Listening to the whole thing, I was surprised by the somewhat...

Listening to the whole thing, I was surprised by the somewhat aggressively positive tone of the presentations and discussions.

seemed very very confident on backpain trial, adult gvhd trial (based on data from expanded access patients including those that had failed Rux) and ability to expand heart indication after initial BLA submission. Also interesting to hear about the manufacturing improvements that are planned.

also some interesting comments made regarding trials, regulatory processes and acceptance of technology - don’t think I had heard the comments about Teva changing clinical endpoint and hence stuffing up phase 3 before